389030 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
GENINUS, Inc. engages in the research and development of NGS (Next Generation Sequencing)-based genome analysis technology and solutions. Its products include the following: CancerSCAN, an NGS cancer diagnosis service; LiquidSCAN, a liquid biopsy NGS test; Celinus, a single-cell genome analysis service; and HealthSCAN, a genetic testing service that tests innate genes to identify diseases that each person is vulnerable to. The company was founded on April 20, 2018 and is headquartered in Seoul, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
389030 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company